Management of de novo accelerated phase chronic myeloid leukemia (ie, treatment-naïve AP CML)

This algorithm describes initial management of de novo CML AP; importantly, management of de novo AP CML differs from that of transformed AP CML (ie, AP CML that arose while the patient was receiving a TKI).
Refer to related UpToDate material for criteria for diagnosis of de novo CML AP, selection of a TKI, assessment of response to TKI, and eligibility for allogeneic HCT.